Generated October 21, 2026 at 8:33 PM ET
· Covers October 21 trading day
· 10 of 248 ready 8-Ks selected
· AI-assisted overview
The day's 8-K filings were led by Getty Images Holdings, which filed prepackaged Chapter 11 petitions in Delaware with a plan that cancels existing equity for no recovery. Two other companies disclosed listing or covenant stress: Direct Digital Holdings will voluntarily delist from Nasdaq and deregister with the SEC, while Nuburu closed its €5.2M Tekne purchase and received a NYSE American delisting warning, and America's Car-Mart added $5.0M in term loans with its default waiver extended to Nov. 1. On the transaction side, Abbott outlined a tax-free spin-off of its ~$8.5B Nutrition business by the end of 2027, and Smith & Wesson closed its $160M Savage Arms acquisition. Leadership, regulatory and earnings items included MillerKnoll naming Jeff Stutz permanent CEO, INmune Bio's UK pre-MAA submission for Ebstrocel, FDA approval of GSK/Ionis's Hibsago, and Lithia Motors reporting Q3 EPS of $13.22 with a 7% dividend increase.
leadership
positive
materiality 0.65
October 21, 2026, 8:00 AM ET
MillerKnoll names Jeff Stutz permanent CEO; sets $1M salary and $1.075M step-up equity grant
- Jeff Stutz, interim CEO since June 30, 2026 and prior COO from September 2025, appointed CEO and board member effective October 21, 2026; board expanded from 10 to 11.
- Offer letter sets $1,000,000 annual base salary, 125% target annual bonus and 400% target long-term incentive opportunity.
- One-time step-up equity grant target value $1,075,000, split 60% performance stock units and 40% restricted stock units under 2026 LTIP.
DRCT
Direct Digital Holdings, Inc.
regulatory
negative
materiality 0.85
October 21, 2026, 5:16 PM ET
Direct Digital Holdings to voluntarily delist from Nasdaq Nov 12; will deregister stock with SEC
- Board authorized withdrawal Oct 20, 2026; Form 25 due on or about Nov 2, delisting effective ~Nov 12, 2026, with Section 12(b) registration ending ~Jan 31, 2027.
- Nasdaq issued its delist determination Oct 1, 2026 after the company failed Listing Rule 5550(b)(1); trading has been suspended since Oct 5, 2026.
- Class A shares now quote on the OTC Pink 'Limited Information' tier as DRCT and are expected to stay there; a higher OTC tier is under discussion only.
M&A
negative
materiality 0.85
October 21, 2026, 6:00 AM ET
Nuburu closes Tekne deal for €5.2M plus €20M earn-out, owns 70%; NYSE American issues delisting warning
- Nuburu Defense bought 745,759 Tekne shares, about 67.1% stake, from Ambrogio D'Arrezzo, Carlo Ulacco and Andrea Lodi for €5.2M; with prior 2.9%, now owns 70%.
- Price: €1.2M paid at Oct. 15, 2026 closing; four €1M installments due Dec. 31, 2026, Jan. 31, Feb. 28 and Mar. 31, 2027; Nuburu jointly liable.
- Earn-out cut to €20M from €29.692M, paid as 5% of Tekne FY2027-2036 revenue, with €2M annual minimum and €20M cap; first payment due June 30, 2028.
M&A
positive
materiality 0.85
October 21, 2026, 9:19 AM ET
Abbott to spin off $8.5B Nutrition business via tax-free distribution by end of 2027
- Nutrition spin-off will hold Similac, PediaSure, Pedialyte, Glucerna and Ensure, with ~$8.5B annual sales, ~16,000 employees and 14 manufacturing sites.
- Remaining Abbott will have ~$42B in sales and ~106,000 employees, focused on medical devices, biowearables, diagnostics and established medicines.
- Separation structured as a tax-free distribution to Abbott shareholders; combined Abbott and Nutrition dividends expected to equal Abbott's current payout.
SWBI
SMITH & WESSON BRANDS, INC.
M&A
positive
materiality 0.82
October 21, 2026, 9:05 AM ET
Smith & Wesson closes $160M Savage Arms buy; sees $0.10/share annual accretion after synergies
- Deal closed Oct 21, 2026: base value $160.0M, adjusted to ~$164.9M; consideration was 8,993,968 SWBI shares at $13.62 plus $42.4M cash (press release cites $37.5M cash).
- Savage posted ~$160M net sales for the 12 months ended Sept 30, 2026; price equals ~7.9x Adjusted EBITDA after $2.5M of expected run-rate synergies.
- Expected ~$18M of incremental EBITDAS annually; EPS accretion of $0.04 in remainder of FY2027, $0.07 full year, ~$0.10 after synergies, excluding acquisition accounting.
regulatory
positive
materiality 0.75
October 21, 2026, 9:00 AM ET
INmune Bio submits Ebstrocel pre-MAA to UK MHRA, targets approval in mid-2027
- Submitted final pre-MAA package for Ebstrocel (CORDStrom) to the UK MHRA on October 20, 2026; full MAA targeted for early February 2027.
- INmune Bio says the revised strategy could accelerate potential UK approval by about six weeks, with possible approval in mid-2027 subject to MHRA review.
- Signed a Master Services Agreement with Uniphar Durbin Ireland to support named-patient access in selected European and MENA markets.
IONS
IONIS PHARMACEUTICALS INC
regulatory
positive
materiality 0.70
October 21, 2026, 4:15 PM ET
FDA approves GSK/Ionis Hibsago (bepirovirsen) for chronic hepatitis B; Ionis earns 10-12% royalties
- FDA approved Hibsago (bepirovirsen) for CHB in adults without cirrhosis, on NrtI therapy ≥6 months, with suppressed HBV DNA and HBsAg ≤3000 IU/ml.
- Phase 3 B-Well pooled data: 19% functional cure (233 of 1,220) vs 0 of 614 on placebo; 26% (200 of 768) in patients with HBsAg ≤1000 IU/ml.
- Approval granted under FDA priority review and Breakthrough Therapy Designation; bepirovirsen is also approved in Japan, with more global decisions expected.
GETY
Getty Images Holdings, Inc.
other material
negative
materiality 1.00
October 21, 2026, 8:01 AM ET
Getty Images files prepackaged Chapter 11; existing equity cancelled with no recovery
- Getty Images Holdings and six subsidiaries filed voluntary Chapter 11 petitions in Delaware on Oct. 21, 2026 to implement a prepackaged plan backed by majority shareholders and funded-debt holders.
- Plan cancels all Class A common stock and other existing equity on the effective date; holders, including majority shareholders, receive no distribution or recovery.
- Chapter 11 filing accelerated about $40.1M USD term loans, €407M euro term loans and a $150M revolving credit facility; enforcement is stayed by the Bankruptcy Code.
earnings
positive
materiality 0.88
October 21, 2026, 8:23 AM ET
Lithia Motors Q3 2026 EPS rose 54% to $13.22; revenue reached $9.9B; dividend raised 7% to $0.75
- Q3 2026 revenue rose 3% to $9.9B; diluted EPS was $13.22, up 54% from $8.61; adjusted EPS was $10.34, up 9%.
- Net income was $292.9M, up 34%; adjusted net income was $229.3M, down 5% from $240.9M.
- Board declared a $0.75 per share dividend payable Nov. 20, 2026 to holders of record Nov. 6, a 7% increase.
CRMT
AMERICAS CARMART INC
debt
negative
materiality 0.72
October 21, 2026, 4:05 PM ET
Car-Mart adds $5M term loan; lenders extend default waiver to Nov 1
- Second Amendment with Silver Point Finance adds $5.0M incremental term loans maturing Oct 30, 2030; $200,000 of fees paid in kind and added to principal.
- Borrowers acknowledged $305,608,825.77 aggregate outstanding loan principal as of Oct 14, 2026.
- Lenders extended the First Amendment waiver of specified events of default and relief from minimum liquidity and Collateral Coverage Ratio covenants to Nov 1, 2026, from Oct 22.